Back to discover
Disease

Edema

Late-stage therapeutic developmentEmerging research
MeSHEdema
3
Publications
24
Clinical trials
12
Associated genes
1
Related proteins
2020
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Approval: Bopediat (EMA)

Regulatory2026-05-29EMA

Approval: Qaialdo (EMA)

Regulatory2023-05-26EMA

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q2 2027.
  • 9 industry developments reported.
Upcoming Milestones
Clinical Milestones11View all 11
Results posted 1
Results expected 4
Recently completed 3
Other updates 3
+3 more in the activity timeline below
Industry & Market9View all 9
+4 more in the activity timeline below
Activity timeline20

Clinical trials

18 sponsors · 3 new · 4 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema

Phase 4 · Recruiting · Centre Hospitalier Universitaire Dijon

ASTRA: A Phase 3 Multi-center, Randomized, Double-Masked, Prospective Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-3)

Phase 3 · Recruiting · Aurion Biotech

A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)

Phase 3 · Recruiting · EyePoint Pharmaceuticals, Inc.

Long-term Need of Ranibizumab Injections With or Without Early Targeted Peripheral Laser Photocoagulation for Treatment of Macular Edema Due to Central Retinal Vein Occlusion

Phase 3 · Active, not recruiting · University of Giessen

A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

Phase 3 · Recruiting · Kodiak Sciences Inc

The Efficacy and Safety of Intravenous HRS8179 for the Prevention and Treatment of Severe Cerebral Edema Following Large Hemispheric Infarction: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II/III Clinical Trial

Phase 2/3 · Recruiting · Beijing Suncadia Pharmaceuticals Co., Ltd
Recruiting

Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema

Phase 4 · Recruiting · Centre Hospitalier Universitaire Dijon

ASTRA: A Phase 3 Multi-center, Randomized, Double-Masked, Prospective Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-3)

Phase 3 · Recruiting · Aurion Biotech

A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)

Phase 3 · Recruiting · EyePoint Pharmaceuticals, Inc.

A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

Phase 3 · Recruiting · Kodiak Sciences Inc

The Efficacy and Safety of Intravenous HRS8179 for the Prevention and Treatment of Severe Cerebral Edema Following Large Hemispheric Infarction: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II/III Clinical Trial

Phase 2/3 · Recruiting · Beijing Suncadia Pharmaceuticals Co., Ltd
Recently completed

A Phase 2/3 Double-Masked, Randomized, 2 Stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema

Phase 2/3 · Completed · Oculis

Multi-Center, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of 8 mg Aflibercept in Chinese Participants With Diabetic Macular Edema

Phase 3 · Completed · Bayer

Phase III Non-inferiority Clinical Study to Evaluate the Efficacy and Safety of Intravitreous PRO-169 Compared to Ranibizumab for Diabetic Macular Edema

Phase 3 · Completed · Laboratorios Sophia S.A de C.V.

Traditional Chinese Medicine and Ranibizumab in the Treatment of Macular Cystoid Edema Associated With Retinal Vein Obstruction.

Phase 4 · Completed · Dongyang People's Hospital

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema

Phase 3 · Completed · Hoffmann-La Roche

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen

Phase 4 · Completed · Nicole Fram M.D.

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20172020
Recent publications

Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations.

The New England journal of medicine · 2020 · 653 cites

Targeting Aquaporin-4 Subcellular Localization to Treat Central Nervous System Edema.

Cell · 2020 · 379 cites

Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.

The New England journal of medicine · 2017 · 375 cites
Major themes1
  • Mutation1
Leading journals2
  • The New England journal of medicine2
  • Cell1
Leading researchers8
  • Ahmed Z1
  • Al-Jubair T1
  • Almutiri S1
  • Bill RM1
  • Bruns R1
  • Chang GC1
  • Chen YM1
  • Cho BC1
Affiliations (unnormalised)6
  • Cumming School of Medicine1
  • From Memorial Sloan Kettering Cancer Center1
  • Harvard Medical School1
  • Institute of Clinical Sciences1
  • Institute of Inflammation and Ageing1
  • Ludwig Maximilian University1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

SCNN1A0.53RPL150.37ECE20.35CDH200.32DPYSL30.32COL8A10.31MCHR20.31TUBGCP30.29SLC37A30.28FAM204A0.28DEUP10.28CACHD10.27

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Large ribosomal subunit protein eL15via RPL150.37

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.

Identifiers
MeSHEdema
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.